Sarepta Therapeutics Inc (NASDAQ:SRPT) CEO Douglas S. Ingram purchased 16,252 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were bought at an average price of $123.07 per share, for a total transaction of $2,000,133.64. Following the completion of the transaction, the chief executive officer now owns 424,405 shares of the company’s stock, valued at $52,231,523.35. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Shares of NASDAQ SRPT opened at $122.98 on Thursday. Sarepta Therapeutics Inc has a 12 month low of $95.21 and a 12 month high of $165.87. The company has a quick ratio of 11.15, a current ratio of 12.17 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of -22.52 and a beta of 2.01. The stock’s 50-day simple moving average is $145.75.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 56.64% and a negative net margin of 165.52%. The business had revenue of $94.67 million for the quarter, compared to analysts’ expectations of $91.05 million. During the same period in the previous year, the firm posted ($1.67) EPS. The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. As a group, analysts anticipate that Sarepta Therapeutics Inc will post -4.42 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $456,000. California State Teachers Retirement System raised its holdings in shares of Sarepta Therapeutics by 6.9% during the second quarter. California State Teachers Retirement System now owns 112,277 shares of the biotechnology company’s stock valued at $17,060,000 after acquiring an additional 7,255 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $312,000. Vanguard Group Inc. raised its holdings in shares of Sarepta Therapeutics by 3.9% during the second quarter. Vanguard Group Inc. now owns 6,232,424 shares of the biotechnology company’s stock valued at $947,017,000 after acquiring an additional 232,752 shares in the last quarter. Finally, Ellington Management Group LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $213,000. 95.57% of the stock is owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.